CAS 1025015-40-0

Fórmula: C21H20N4O

InChI: InChI=1S/C21H20N4O/c1-2-7-17(8-3-1)10-11-19-21(26-16-15-25-13-4-5-14-25)24-18-9-6-12-22-20(18)23-19/h1-3,6-9,12H,4-5,13-16H2

Chave InChI: MNYJJHBAEYKXEG-UHFFFAOYSA-N

SMILES: C1CCN(C1)CCOC2=NC3=C(N=CC=C3)N=C2C#CC4=CC=CC=C4

GK921

CAS: 1025015-40-0

GK921

Fórmula: C₂₁H₂₀N₄O

Pureza: ≥95%

Peso molecular: 344.41

Ref: 54-BUP05940

GK921

CAS: 1025015-40-0

Fórmula: C₂₁H₂₀N₄O

Pureza: 99%

Cor e Forma: Solid

Peso molecular: 344.4097

Ref: IN-DA008TGG

GK921

CAS: 1025015-40-0

3-(Phenylethynyl)-2-(2-(pyrrolidin-1-yl)ethoxy)pyrido[2,3-b]pyrazine

Fórmula: C₂₁H₂₀N₄O

Pureza: 99%

Peso molecular: 344.41

Ref: IN-DG629835

GK921

CAS: 1025015-40-0

GK921 is a transglutaminase 2 (TGase) inhibitor.

Fórmula: C₂₁H₂₀N₄O

Pureza: 97.44% - 99.92%

Cor e Forma: Yellow Solid

Peso molecular: 344.4097

Ref: TM-T3968

GK921

CAS: 1025015-40-0

GK921 is a drug candidate that inhibits the PD-1 pathway. It has been shown to inhibit tumor growth in xenograft models of cancer by inducing autophagy and inhibiting cell proliferation. GK921 was found to be effective in treating mouse models of cancer with radiation therapy and lysine residues, which are predictive biomarkers for efficacy. The drug also has inhibitory effects on mammalian cells through the inhibition of growth factor signaling pathways. GK921 is currently being studied in clinical trials as a treatment for cancer patients with risk groups such as lung adenocarcinoma and non-small cell lung cancer.

Fórmula: C₂₁H₂₀N₄O

Pureza: Min. 95%

Peso molecular: 344.41 g/mol

Ref: 3D-ARB01540